Surrozen appoints Andrew Maleki as Chief Financial Officer
- New Appointment: Andrew Maleki has been appointed as the CFO of Surrozen.
- Experience: He has over a decade of experience in the biotech industry, focusing on corporate strategy, business development, and operational leadership.
- Capital Raising: Maleki has played a significant role in raising over $500 million in capital throughout his career.
- Previous Role: Before joining Surrozen, he was involved in corporate development and program leadership at Lassen Therapeutics, influencing portfolio strategy and business development.
Trade with 70% Backtested Accuracy
Analyst Views on SRZN
About SRZN
About the author
Surrozen Reports Q2 Profit on Gains
Financial Performance: Surrozen reported a GAAP EPS of $2.55 for Q2 2025, significantly exceeding expectations due to non-cash gains, while also achieving a net income of $39.7 million despite ongoing operating losses and increased research expenses.
Pipeline and Strategy: The company is advancing its ophthalmology drug candidates SZN-8141 and SZN-8143 targeting retinal diseases, with plans to submit an IND application in 2026, while relying on strategic partnerships for revenue and expertise amidst challenges in clinical trial timelines and cash management.
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Leadership Changes and Advisory Board Formation: Surrozen has appointed Daniel Chao, M.D., Ph.D., as Vice President of Clinical Development and established a Clinical Advisory Board of leading retinal specialists to enhance its ophthalmology pipeline focused on severe eye diseases.
Financial Performance and Pipeline Progress: The company reported a net income of $39.7 million for Q2 2025, attributed to increased research service revenue and a strong cash position, while advancing its lead candidates SZN-8141 and SZN-8143 towards clinical trials.
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
Patent Issuance: Surrozen, Inc. has been granted U.S. Patent No. 12,297,278 for its SWAP™ technology, which covers novel tetravalent Wnt surrogate molecules designed to enhance Wnt pathway signaling for therapeutic applications.
Product Development: The company is advancing multiple product candidates targeting retinal diseases, including SZN-8141 and SZN-8143, which combine Frizzled agonism and VEGF antagonism to potentially improve treatment outcomes over existing therapies.
HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $32 Price Target
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
Business Focus and Developments: Surrozen, Inc. has shifted its focus to developing treatments for severe eye diseases using its Wnt pathway expertise, discontinuing its SZN-043 project due to insufficient clinical benefits. The company is advancing its lead candidates, SZN-8141 and SZN-8143, towards clinical studies expected to begin in 2026.
Financial Performance: For the first quarter of 2025, Surrozen reported a net loss of $27 million, an increase from $8.8 million in the same period last year, while cash reserves rose significantly to $101.6 million following a private placement financing.
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Financial Performance: Surrozen, Inc. reported a net loss of $63.6 million for the full year 2024, an increase from $43.0 million in 2023, while collaboration and license revenue reached $10 million due to a milestone achievement. The company also completed a financing round that raised $175 million to support its ophthalmology programs.
Research and Development Focus: Surrozen is prioritizing its pipeline for severe eye diseases, particularly through its Wnt pathway modulation technologies, with ongoing development of novel treatment options like SZN-8141 and SZN-8143 aimed at conditions such as Diabetic Macular Edema and Age-Related Macular Degeneration.
Surrozen Reports Q2 Profit on Gains
Financial Performance: Surrozen reported a GAAP EPS of $2.55 for Q2 2025, significantly exceeding expectations due to non-cash gains, while also achieving a net income of $39.7 million despite ongoing operating losses and increased research expenses.
Pipeline and Strategy: The company is advancing its ophthalmology drug candidates SZN-8141 and SZN-8143 targeting retinal diseases, with plans to submit an IND application in 2026, while relying on strategic partnerships for revenue and expertise amidst challenges in clinical trial timelines and cash management.
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Leadership Changes and Advisory Board Formation: Surrozen has appointed Daniel Chao, M.D., Ph.D., as Vice President of Clinical Development and established a Clinical Advisory Board of leading retinal specialists to enhance its ophthalmology pipeline focused on severe eye diseases.
Financial Performance and Pipeline Progress: The company reported a net income of $39.7 million for Q2 2025, attributed to increased research service revenue and a strong cash position, while advancing its lead candidates SZN-8141 and SZN-8143 towards clinical trials.
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
Patent Issuance: Surrozen, Inc. has been granted U.S. Patent No. 12,297,278 for its SWAP™ technology, which covers novel tetravalent Wnt surrogate molecules designed to enhance Wnt pathway signaling for therapeutic applications.
Product Development: The company is advancing multiple product candidates targeting retinal diseases, including SZN-8141 and SZN-8143, which combine Frizzled agonism and VEGF antagonism to potentially improve treatment outcomes over existing therapies.
HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $32 Price Target
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
Business Focus and Developments: Surrozen, Inc. has shifted its focus to developing treatments for severe eye diseases using its Wnt pathway expertise, discontinuing its SZN-043 project due to insufficient clinical benefits. The company is advancing its lead candidates, SZN-8141 and SZN-8143, towards clinical studies expected to begin in 2026.
Financial Performance: For the first quarter of 2025, Surrozen reported a net loss of $27 million, an increase from $8.8 million in the same period last year, while cash reserves rose significantly to $101.6 million following a private placement financing.
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Financial Performance: Surrozen, Inc. reported a net loss of $63.6 million for the full year 2024, an increase from $43.0 million in 2023, while collaboration and license revenue reached $10 million due to a milestone achievement. The company also completed a financing round that raised $175 million to support its ophthalmology programs.
Research and Development Focus: Surrozen is prioritizing its pipeline for severe eye diseases, particularly through its Wnt pathway modulation technologies, with ongoing development of novel treatment options like SZN-8141 and SZN-8143 aimed at conditions such as Diabetic Macular Edema and Age-Related Macular Degeneration.
